The role of TNF-α in rheumatoid arthritis: a focus on regulatory T cells

Mark Farrugia, Byron Baron*

Center for Molecular Medicine and Biobanking, Faculty of Medicine and Surgery, University of Malta, Msida, Malta

ARTICLE INFO

Article history:
Received: June 4, 2016
Revised: September 7, 2016
Accepted: September 12, 2016
Published online: September 15, 2016

Keywords:
rheumatoid arthritis
regulatory T cells
TNF-α therapy
joint inflammation

ABSTRACT

The autoimmune disorder rheumatoid arthritis (RA) causes chronic inflammation and destruction of joints. T cells are a predominant component of the synovial environment in RA, however the functional role of these cells is not yet fully understood. This is in part due to the fact that the balance and importance of the relation of Treg with T-effector cells in RA is still under investigation. The current treatment regimen for this debilitating disease focuses on controlling symptoms and preventing further joint damage through the use of therapies which affect different areas of the immune system at the synovium. One of the main therapies involves Tumor Necrosis Factor alpha (TNF-α) inhibitors. In the RA immune-environment, TNF-α has been shown to have an influential and extensive but as yet poorly understood effect on Treg function in vivo, and undoubtably an important role in the treatment of RA. Interestingly, the high levels of TNF-α found in RA patients appear to interfere with the mechanisms controlling the suppressive function of Treg.

Relevance for patients: This review focuses on the conflicting literature available regarding the role played by Treg in RA and the impact of TNF-α and anti-TNF-α therapies on Treg in this scenario. Individuals suffering from RA can benefit from better insight of the treatment mechanisms of the immunologic processes which occur throughout this disease, as current treatments for RA focus on several different areas of the immune system at the synovial compartment.

1. Introduction

Rheumatoid arthritis (RA) is an autoimmune disorder that manifests itself as a chronic inflammation of the lining of the joints, with significant morbidity and mortality rates if left untreated [1]. RA is characterized by synovial inflammation and hyperplasia (swelling), autoantibody production (rheumatoid factor (RF) and anti-citrullinated protein antibody (AC-PA)), cartilage and bone destruction, and systemic features, including cardiovascular, pulmonary, psychological, and skeletal disorders [2]. Possible risk factors for the development of RA include genetic background, smoking, silica inhalation and periodontal disease [1].

A hyperplastic synovium is the major contributor to the cartilage damage in RA. The loss of the protective effects of the synovium result in the alteration of the protein-binding characteristics of the cartilage surface, promoting synoviocytes (FLS) adhesion and invasion. These processes lead to the destruction of the surface [2]. Bone erosion then follows rapidly (affecting 80% of patients within 1 year after diagnosis [1]). Cytokines present in the synovial fluid, particularly macrophage colony-stimulating factor (M-CSF) and receptor activator of NF-κB ligand (RANKL), promote osteoclast differentiation and invasion of the periosteal surface adjacent to articular cartilage [3]. Tumor Necrosis Factor alpha (TNF-α) and Interleukin (IL) -1, 6, and potentially 17 amplify osteoclast differentiation and activation.

Studies in Europe have shown that there is a gradient in the prevalence of RA, starting from a low prevalence in the South (e.g. Italy 0.31%) [4], to a higher prevalence in the North (e.g. Finland 0.8%) [5]. While no formal epidemiological studies on RA have been carried out in Malta yet, a total of approximately 600 patients with the disease are followed up at the Rheumatology Clinic at St. Luke's Hospital, giving a preva-
The use of different case definitions makes the estimates vary as widely as 25 to 115 per 100,000 [7]. The annual incidence rate of RA recorded in studies varies between 20 and 50 cases per 100,000 in Northern European countries, but there are indications that it may be lower in Southern European countries [8,9]. Studies of the incidence and prevalence of RA suggest variations between different populations even within the same country. Possible explanations include regional variation in behavioral factors, climate, environmental exposures, RA diagnosis, and genetic factors [7].

Currently, treatment focuses on controlling symptoms and preventing further joint damage. Medications used in the treatment of RA include non-steroidal anti-inflammatory drug (NSAIDs), disease-modifying anti-rheumatic drug (DMARDs), TNF-α inhibitors, IL-6 inhibitors, T-cell activation inhibitors, B-cell depleters, Janus kinase (JAK) inhibitors, and steroids [10] (Figure 1). Since all current treatments for RA are focusing on different areas of the immune system at the synovial compartment, a good understanding of the immunologic processes which occur throughout RA is vital for a better insight of the treatment mechanisms themselves.

2. Synovial immunological processes

Several of the risk alleles linked to RA consistently map functionally with immune regulation such as the nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB)-dependent signaling, T-cell stimulation, activation, and functional differentiation. This suggests that these immunologic pathways are amongst the key modulators of the development of the autoimmune inflammation in RA [11-13].

The costimulation-dependent interactions among dendritic cells, T cells, and B-cells are thought to occur primarily in the lymph node, generating an autoimmune response to citrulline-containing self-proteins [2]. The inflammation of the synovial membrane (synovitis) is then caused by the infiltration of leukocytes in the synovial compartment. Leukocyte migration is enabled through various pathways, mainly through the activation of endothelial tissue in synovial micro-vessels, resulting in an increase in expression of adhesion molecules and chemokines [14]. This and other processes result in the build-up of inflammatory synovial tissue (Figure 2).

A variety of innate effector cells, including macrophages, mast cells, and natural killer cells, are found in the synovial membrane, while neutrophils reside mainly in synovial fluid. The main role of macrophages in this scenario is that of releasing cytokines (e.g., TNF-α and interleukin-1, 6, 12, 15, 18, and 23), reactive oxygen intermediates, nitrogen intermediates, production of prostanoids and matrix-degrading enzymes, phagocytosis, and antigen presentation [15]. Neutrophils on the other hand contribute to synovitis by
synthesising prostaglandins, proteases, and reactive oxygen intermediates [16]. These findings provide evidence that activation of the innate immune pathway contributes to synovitis.

It has become more apparent from various reports in the literature that cytokines play an integral role in the activation and maintenance of the innate immune pathway. Cytokine production that arises from numerous synovial cell populations is central to the pathogenesis of RA [13]. TNF-α is one such cytokine and plays a fundamental role through the activation of cytokine and chemokine expression, expression of endothelial-cell adhesion molecules, protection of synovial fibroblasts, promotion of angiogenesis, suppression of regulatory T cells, and induction of pain [17,18]. The central role of this cytokine has been repeatedly confirmed by a successful therapeutic blockade of membrane and soluble TNF-α in patients with RA.

3. TNF-α

TNF-α is an inflammatory cytokine consisting of a trimeric protein encoded within the major histocompatibility complex. Its first identified form was the 17 kDa secreted form, but further research then showed that a noncleaved 27 kDa precursor form was also present in transmembrane form [19]. TNF-α and its specific receptors TNFR1/TNFR2 are the major members of a gene superfamily of ligand and receptors which are responsible for regulating essential biologic functions. The extracellular domains of TNFR1 and TNFR2 are homologous and have similar affinity for TNF-α, however the cytoplasmic regions of these two receptors are distinct and mediate different downstream events. TNFR1 signalling is the major mechanistic pathway responsible for the effects of TNF-α [20]. These receptors are expressed on all somatic cells.

4. Role of T cells in rheumatoid arthritis

Even though T cells are a predominant component of the synovial environment in RA, the functional role of T cells is not yet fully understood. This is mainly due to the fact that lymphocytes, including T cells, act and react according to the presence and numbers of other subsets of lymphocytes, and this systematic approach to immunity has only recently started to be investigated in detail [21]. Therefore, it is vital to understand all of the main protagonists in the synovium in our assessment of the immunological processes taking place.

Activated CD4+ T cells stimulate monocytes, macrophages, and synovial fibroblasts to produce the cytokines IL-1, IL-6, and TNF-α [22]. Activated CD4+ T cells also stimulate B-cells and these produce immunoglobulins, including the RF. The precise immunologic role of RF is still unknown, but it may involve the activation of complement through the formation of immune complexes [23]. Activated CD4+ T cells also express RANKL, and as explained previously, this stimulates osteoclast differentiation. Thus these activated T cells give rise to cartilage erosion caused by excessive osteoclasts [24].

RA is conventionally considered to be a disease mediated by type 1 helper T cells, however there is increased attention on the role of type 17 helper T cells (Th17). Th17 is a subset of T cells that produces interleukin-17A, 17F, 21, and 22 and TNF-α [25,26]. Other cytokines which support the differentiation of Th17 cells are macrophage-derived and dendritic cell–derived transforming growth factor β (TGF-β) and IL-1, 6, 21, and 23 [26].

It is interesting to note that IL-6 suppresses the differentiation of regulatory T cells (Tregs), thus shifting T-cell homeostasis toward inflammation rather than autoregulation [27]. It is now well accepted that Tregs are critically involved in immune tolerance and homeostasis. Tregs that are detected in tissues from patients with RA seem to have limited functional capability, as inferred via Forkhead box P3 (FoxP3) transcript levels, which are lower in the synovial membrane compared to those in peripheral blood or synovial fluid [28].

In RA, there are two distinct classes of Tregs depending on their location: those found in the peripheral blood and those at the site of inflammation, usually studied in the synovial fluid (SF) [29-31]. Different studies report different accumulation numbers of Tregs in the peripheral blood between healthy individuals and RA patients, varying from reports of decrease to an increase in Tregs, comparatively [32-36]. In many scenarios, however, the lack of function of the Tregs themselves seems to be observed. FoxP3+ Tregs sampled from the SF of RA patients are able to suppress the proliferation of effector T cells [31], but Ehrenstein et al. reported that, while Tregs from RA patients do suppress proliferation, they are defective in their ability to suppress pro-inflammatory cytokine production [34], and thus this process is not regulated, resulting in inflammation. It is important to note that this study was done with Tregs obtained from peripheral blood rather than SF. On the other hand, a conflicting recent study also performed using Tregs obtained from peripheral blood, shows that there is no significant difference between the suppressive effects of FoxP3+ Tregs on certain cytokines and the proliferation of effector T cells, between Tregs obtained from healthy individuals and from RA patients [37].

Various studies provide compelling evidence that CD4+ FoxP3+ Tregs cells play an indispensable role in maintaining immune homeostasis and in suppressing deleterious excessive immune responses [38]. There are various subsets of Tregs, with various effects on effector T cells in the autoimmune scenario [39]. Any disregulation or loss of function in Tregs will result in an upregulation of T-effector cells and any other cell type under suppression by Tregs. Thus it is important to understand better how TNF-α, being one of the most present and influential cytokines in the synovial immuno-environment, affects the function of Tregs.

5. Effect of TNF-α on regulatory T-cell function in rheumatoid arthritis

TNF-α and IL-7 are two cytokines which act against the suppressive activity of human Tregs [40]. High levels of TNF-α are found in both the serum and synovial fluid of RA patients,
and therefore this might be one of the factors which result in defective Treg function [41]. Treatment of these patients with infliximab, an anti-TNF-α therapy, gave rise to an adaptive FoxP3+ CD62L− Treg population, which was able to suppress cytokine production of effector T cells via a TGF-β and IL-10 pathway [42]. The fact that the naturally-occurring CD62L+ Treg remained defective in infliximab-treated patients clearly showed that TNF-α was responsible in promoting the development of a new dysfunctional subset of FoxP3+ Tregs. Another study highlighting the importance of TNF-α in RA vis-à-vis FoxP3+ Treg reported that overexpression of TNF-α in human TNF-α transgenic mice led to the development of arthritis, with an increased number of Treg expressing the TNF receptor II (TNFRII) [43]. TNFRII is a required receptor for TNF-α interactions [44]. The TNF-α overexpression did not inhibit the suppressive activity of the Tregs, however the Treg still failed to control inflammation. When TNF-α was blocked, a further increase in the frequency of Tregs was observed, and these Tregs had upregulated CTLA-4 expression, resulting in enhanced suppressor activity [43]. The TNF-α also induced the differentiation of a CD62L− Treg population as observed in the previous study [42].

These studies suggest that TNF-α plays an important role in the inhibition of FoxP3+ Treg suppressive function, particularly in suppressing inflammation. Further to this, it has been shown that TNF-α signaling via TNFRII downregulates FoxP3 expression in humans in both naturally-occurring Treg and adaptive Treg, and this results in the inhibition of Treg suppressive activity [45]. Another study done using human cell cultures showed that during the inhibition of active Treg via TNF-α signaling of the TNFRII receptor, the TNF-α activated the canonical NF-κB pathway and induced a pro-inflammatory phenotype [46], however in this case FoxP3 expression was not affected. The inhibition of Treg suppressive activity could be reversed by treatment with anti-TNFRII antibody. This shows that TNF-α signaling via TNFRII may be one mechanism which leads to Treg defects in RA. This study was performed using both Tregs from peripheral blood and synovial fluid and the results showed similar trends in both types of Treg.

Another way TNF-α might inhibit Treg suppressive activity is by influencing the formation of the immunological synapse between Tregs and antigen presenting cells (APCs) [47]. Although for effector T cells, protein kinase C-θ (PKC-θ) recruitment to the immunological synapse is necessary for full T-cell activation, for FoxP3+ Tregs, PKC-θ is concealed from the immunological synapse. A study was conducted in which a model system on supported planar bilayers containing the mobile fluorescently labelled intercellular adhesion molecule-1 (ICAM-1), anti-CD3 antibodies and CD4+CD25+ effector T cells or CD4+CD25+ Tregs (freshly isolated from peripheral blood) was devised, in order to emulate the immunological synapse. Addition of TNF-α to this model increased the PKC-θ recruitment to the Treg immunological synapse, and this inhibited their suppressive activity. This contrasts with the fact that after blocking PKC-θ, Treg function was enhanced [47]. This study showed that inhibition of PKC-θ might protect Treg from inactivation by TNF-α and this restores the suppressive function of defective Treg in RA patients. Disc large homolog 1 (Dlgh1) is another identified molecule involved in the immunological synapse formation which regulates Treg function independently of PKC-θ [48]. Dlgh1 was found to be recruited to the immunological synapse four times as much in Tregs than in effector T cells. It was also found that Tregs from RA patients with active disease had defective Dlgh1 recruitment to the immunological synapse. This defective recruitment resulted in reduced suppressive activity of Treg. Exposing healthy control Tregs to TNF-α decreased the Dlgh1 recruitment and thus also reduced Treg suppressive activity [48]. These findings suggest that in FoxP3+ Tregs, PKC-θ-mediated negative and Dlgh1-mediated positive pathways seem to regulate suppressive function independently, and in RA, one or both of these pathways may be defective as a possible consequence of TNF-α [49].

TNF-α was also found to interact directly with the DNA-binding activity of the FOXP3 gene in Treg [50]. In this analysis done on human cells obtained from both the peripheral blood and the synovial fluid of RA patients it was shown that TNF-α - TNF receptor-binding induces increased expression of protein phosphatase 1 (PP1). PP1 dephosphorylates Ser418 in the DNA-binding domain of the FoxP3 transcription factor, and this in turn reduces its DNA-binding activity, thus impairing the suppressive function of Treg.

Interestingly, although TNF-α is a major pro-inflammatory cytokine, there is increasing evidence that indicates TNF-α also has immunosuppressive feedback effects, as was demonstrated in a study where both resting and activated mouse peripheral FoxP3+ Tregs purified from lymph node expressed remarkably higher surface levels of TNFRII than effector T cells in vitro [51]. In the same study it was observed that in co-cultures of Treg and effector T cells, suppression of effector T-cell proliferation by Treg was initially observed after exposure to TNF-α, however longer exposure to TNF-α restored the suppressive effects. Furthermore, TNF-α expanded Treg populations in this study, and these TNF-α-expanded Treg had up-regulated expression of CD25 and FoxP3, enhancing the suppressive activity of these Treg. Thus in this study the stimulatory effect of TNF-α on Treg resembled the reported costimulatory effects of TNF-α on effector T cells. Another study to determine the effect of TNF-α on Treg showed that when Treg cells were cultured for 20 h with or without IL-2 before the suppression assays, the presence of TNF in the pre-culture had no effect on their suppressive function in any assay condition [52]. This work also showed that in the presence of IL-2, the effects of TNF on human Tregs in a 3-day culture of whole CD4+ T cells resulted in an increased proportion of Tregs and the upregulation of FOXP3 expression. A suggestion for the slower response of Treg to TNF-α could be a delayed immunosuppressive feedback effect [51]. Another study concludes that human Tregs obtained from the buffy coat of healthy donors which
were deficient in TNFRII were not able to control inflammatory responses in vivo [53]. TNFRII expression on human Tregs present in the synovial fluid of RA patients is also up-regulated [45], presumably reflecting their enhanced suppressive capacity [33]. It is not clear whether TNFRII+ FoxP3+ Tregs are more functionally suppressive (Figure 3).

Diverse roles of TNF-α in the immune response may be partly explained by the existence of two forms of this cytokine: a membrane-bound TNF-α (mTNF-α), and TNF-α which is cleaved from the membrane and released as a soluble cytokine (sTNF-α) [54]. Moreover, TNFR1 and TNFRII have different expression patterns and affinities for mTNF-α or sTNF-α, and may transduce signals with opposite outcomes. TNFRII binds with higher affinity to mTNF-α than to sTNF-α [55].

6. anti-TNF-α therapy effects and future work

It is clear from the conflicting literature above, that we are still far from deducing the exact role and effect of TNF-α on Tregs in the RA scenario. TNF-α seems to interfere with the mechanisms controlling Treg suppressive function, and therefore it is plausible to predict that anti-TNF-α therapies would counter this effect. In fact, studies show that anti-TNF-α therapy has a regulatory effect on the immune system of RA patients by promoting an increase in the proportion of Tregs and suppressing effector T cells [56]. One such recent study showed that the anti-TNF antibody adalimumab promoted the interaction between monocytes and Tregs from RA patients by binding to monocyte membrane bound TNF, enhancing its expression and its binding to TNF-R1I expressed on Tregs [57]. This resulted in adalimumab-expanded functional FoxP3+ Tregs able to suppress Th17 cells through an IL-2/STAT5-dependent mechanism. This study demonstrated that a therapeutic antibody thought to act by blocking TNF-α can also enhance the regulatory properties of this pro-inflammatory cytokine.

However, clinical trials have accumulated evidence that anti-TNF-α therapies might promote rather than suppress certain forms of autoimmunity. In RA, anti-TNF-α therapy is sometimes associated with adverse events, such as multiple sclerosis and lupus [58]. Cases of juvenile arthritis patients who developed type 1 diabetes have been reported during therapy with a TNF-α antagonist [59,60].

TNF-α without a doubt has an important role in the treatment of RA, and it has been shown to have a powerful, varied and yet poorly understood effect on Treg function in vivo in the RA immune-environment. Although anti-TNF-α therapies have been widely used to treat RA with significant clinical result, more research is still needed to understand better the total effect of such therapies on all cell types involved in the synovial immune-environment. Anti-TNF-α therapies might exhibit serious side effects, and the mechanisms leading to such side effects can be investigated further to find methods of suppressing them. Alternate routes to suppress the over-reactive effector T cells as well as activate and enhance the Treg subsets can be investigated, whilst working to obtain a broader and clearer picture of the effect TNF-α has on Tregs and RA in general.

Disclosure

The authors declare no conflict of interest.

References

[1] Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MC, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JMW, Hobbis K, Huizinga TWJ, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawksa-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-2581.

[2] McInnes IB, Schett G. The Pathogenesis of Rheumatoid Arthritis. N Engl J Med 2011; 365: 2205-2219.
[3] Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998; 152: 943-951.

[4] Cimmino MA, Zampogna A, Murroni S, Baruffi S, Alessio G, Maio T, Mela GS. Methodology of an epidemiologic prevalence study in rheumatology: the Chiavari study. Reumatismo 2002; 54: 40-47.

[5] Aho K, Kaipiaainen-Seppanen O, Heloaara M, Klaukka T. Epidemiology of rheumatoid arthritis in Finland. Semin Arthritis Rheum 1998; 27: 325-334.

[6] Mallia C. Treating Rheumatoid Arthritis Yesterday and Today. MMJ 2004; 16: 18-21.

[7] Carmona L, Cross M, Williams B, Lassere M, March L. Rheumatoid arthritis. Best Practice Res Clin Rheumatol 2010; 24: 733-745.

[8] Carbonell J, Cobo T, Balsa A, Descalzo MA, Carmona L. The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. Rheumatology 2008; 47: 1088-1092.

[9] Pedersen JK, Kjaer NK, Svendsen AJ, Horslev-Petersen K. Incidence of rheumatoid arthritis from 1995 to 2001: impact of ascertainment from multiple sources. Rheumatol Int 2009; 29: 411-415.

[10] Kumar P and Banik S. Pharmacotherapy Options in Rheumatoid Arthritis. Clin Med Insights Arthritis Musculoskelet Disord 2013; 6: 35-43.

[11] Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM, Conn MT. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004; 75:330-337.

[12] Plenge RM, Cotsapas C, Davies L, Price AL, De Bakker PI, Maller J, Pe'er I, Burtt NP, Blumenstiel B, DeFelice M, Parkin M. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007; 39: 1477-1482.

[13] Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, De Bakker PI, Le JM, Lee HS, Bhatwalla F, Li W. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357: 977-986.

[14] Szekanecz Z, Pakozdi A, Szempey E, Besenyei T, Koch AE. Chemokines and angiogenesis in rheumatoid arthritis. Front Biosci (Elite Ed) 2009; 1: 44-51.

[15] Liew FY, McInnes IB. The role of innate mediators in inflammatory response. Mol Immunol 2002; 38: 887-890.

[16] Cascão R, Rosário HS, Souto-Carneiro MM, Fonseca JE. Neutrophils in rheumatoid arthritis: more than simple final effectors. Autoimmun Rev 2010; 9: 531-535.

[17] Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996; 85: 307-310.

[18] Hess A, Axmann R, Rech J, Finzel S, Heindl C, Kreitz S, Segerova M, Saake M, Garcia M, Kollias G, Straub RH. Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci USA 2011; 108: 3731-3736.

[19] Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Michael K. A non secretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 1990; 63: 251-258.

[20] Amiot F, Fitting C, Tracey KJ, Cavaillon JM, Dauty F. Lipo-polsaccharide-induced cytokine cascade and lethality in LT alpha/TNF alpha-deficient mice. Mol Med 1997; 3: 864-875.

[21] Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-361.

[22] Isler P, Vey E, Zhang JH, Dayer JM. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. Eur Cytokine Netw 1993; 4: 15-23.

[23] Burbano C, Rojas M, Vásquez G, Castaño D (2015). Microparticles That Form Immune Complexes as Modular Structures in Autoimmune Responses. Mediators Inflamm 2015; Article ID 26759.

[24] Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-309.

[25] Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol 1998; 161: 409-414.

[26] Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-898.

[27] Zheng SG. Regulatory T cells vs Th17: differentiation of Th17 versus Treg, are the mutually exclusive? Am J Clin Exp Immunol 2013; 2: 94-106.

[28] Behrens F, Himsel A, Rehart S, Stanzczyk J, Beutel B, Zimmermann SY, Koelho U, Möller B, Gay S, Kaltwasser JP, Pfeilsichter JM. Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1151-1156.

[29] van Amelsfort JM, Jacobs KM, Bijlsma JW, Lefeber FP, Taams LS. CD4+(+)/CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004; 50: 2775-2785.

[30] Liu MF, Wang CR, Fung LL, Lin LH, Tsai CN. The presence of cytokine-suppressive CD4+ CD25+ T cells in the peripheral blood and synovial fluid of patients with rheumatoid arthritis. Scand J Immunol 2005; 62: 312-317.

[31] Möttönen M, Heikkinen J, Mustonen L, Isomäki P, Luukkainen R, Lassila O. CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are nototypic and functional characteristics of regulatory T cells are mutually exclusive? Am J Clin Exp Immunol 2009; 4: 215-223.
form of juvenile idiopathic arthritis. J Immunol 2004; 172: 6435-6443.

[34] Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy. J Exp Med 2004; 200: 277-285.

[35] Lawson CA, Brown AK, Bejarano V, Douglas SH, Burgoyne CH, Greenstein AS, Boylston AW, Emery P, Ponchel F, Isaacs JD. Early rheumatoid arthritis is associated with a deficit in the CD4 + CD25 high regulatory T cell population in peripheral blood. Rheumatology 2006; 45: 1210-1217.

[36] Xiao H, Wang S, Miao R, Kan W. TRAIL is associated with impaired regulation of CD4 + CD25- T cells by regulatory T cells in patients with rheumatoid arthritis. J Clin Immunol 2011; 31: 1112-1119.

[37] Walter GJ, Fleksens V, Frederiksen KS, Rajasekhar M, Menon B, Gerwien JG, Evans HG, Taams LS. Phenotypic, Functional, and Gene Expression Profiling of Peripheral CD45RA+ and CD45RO+ CD4+ CD25+ CD127low Treg Cells in Patients with Chronic Rheumatoid Arthritis. Arthritis Rheumatol 2016; 68: 103-116.

[38] Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133: 756-767.

[39] Farrugia M, Baron B. Role of Regulatory T-cells in Oral Tolerance and Immunotherapy. Biochem Physiol 2016; 5: 2.

[40] van Amelsfort JM, van Roon JA, Noordegraaf M, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS. Proinflammatory mediator-induced reversal of CD4+, CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis. Arthritis Rheum 2007; 56: 732-742.

[41] Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 1990; 49: 665-667.

[42] Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007; 204: 33-39.

[43] Biton J, Semerano L, Delavallée L, Lemeiter D, Laborie M, Grouard-Vogel G, Boissier MC, Bessis N. Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis. J Immunol 2011; 186: 3899-3910.

[44] Chandrasekharan UM, Siemionow M, Unsal M, Yang L, Popptic E, Bohn J, Ozer K, Zhou Z, Howe PH, Penn M, DiCorleto PE. Tumor necrosis factor α (TNF-α) receptor-II is required for TNF-α-induced leukocyte-endothelial interaction in vivo. Blood 2007; 109: 1938-1944.

[45] Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE. TNF downmodulates the function of human CD4 + CD25hi T- regulatory cells. Blood 2006; 108: 253-261.

[46] Nagar M, Jacob-Hirsch J, Vernitsky H, Berkun Y, Ben-Horin S, Amariglio N, Bank I, Kloog Y, Rechavi G, Goldstein I. TNF activates a NFkappaB-regulated cellular program in human CD45RA-regulatory T cells that modulates their suppressive function. J Immunol 2010; 184: 3570-3581.

[47] Zanin-Zhorov A, Ding Y, Kumari S, Attur M, Hippen KL, Brown M, Blazar BR, Abramson SB, LaFaille JJ, Dustin ML. Protein kinase C-theta mediates negative feedback on regulatory T cell function. Science 2010; 328: 372-376.

[48] Zanin-Zhorov A, Lin J, Scher J, Kumari S, Blair D, Hippen KL, Blazar BR, Abramson SB, LaFaille JJ, Dustin ML. Scaffold protein Disc large homolog 1 is required for T-cell receptor-induced activation of regulatory T-cell function. Proc Natl Acad Sci U S A 2012; 109: 1625-1630.

[49] Coeles FAH, Isaacs JD and Anderson AE. Treg Cells in Rheumatoid Arthritis: An Update. Curr Rheumatol Rep 2013; 15:1-9.

[50] Nie H, Zheng Y, Li R, Guo TB, He D, Fang L, Liu X, Xiao L, Chen X, Wan B, Chin YE. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat Med 2013; 19, 322-328.

[51] Chen X, Bäumel M, Männel DN, Howard OZ, Oppenheim JJ. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol 2007; 179: 154-161.

[52] Zaragoza B, Chen X, Oppenheim JJ, Baeyens A, Gregoire S, Chader D, Gorochov G, Miyara M, Salomon BL. Suppressive activity of human regulatory T cells is maintained in the presence of TNF. Nat Med 2016; 22: 16-17.

[53] van Mierlo GJ, Scherer HU, Hameetman M, Morgan ME, Flierman R, Huizinga TW, Toes RE. Cutting edge: TNFR-I/II is required for the development of TNF. Nat Med 2013; 109: 1625-1630.

[54] Black, R. A., C. T. Rauch, C. J. Kozlosky, J. J. Peschon, J. L. Slack, M. F. Wolfson, B. J. Castner, K. L. Stocking, P. Reddy, S. Srinivasan, Nelson N. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-733.

[55] MacEwan DJ. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 2002; 14: 477-492.

[56] Huang Z, Yang B, Shi Y, Cai B, Li Y, Feng W, Fu Y, Luo L, Wang L. Anti-TNF-α therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis. Cell Immunol 2012; 279: 25-29.

[57] Nguyen DX, Ehrenstein MR. Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis. J Exp Med 2016; 213: 1241-1253.

[58] Kodama S, Davis M, Faustman DL. The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis. Cell Mol Life Sci 2005; 62: 1850-1862.

[59] Bloom BJ. Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43: 2606-2608.

[60] Tack CJ, Kleijwegt FS, Van Riel PL, Roep BO. Development of type 1 diabetes in a patient treated with anti-TNF-alpha therapy for active rheumatoid arthritis. Diabetologia 2009; 52: 1442-1444.